RE:RE:RE:RE:RE:Just for fun...a $500 million USD offerHi ledrog.
One of the things that stands out to me is that since June 2013 when the ASSURE trial failed to meet the PAV regression target there has been nothing but steady positive results from apabetalone. The degree of understanding of apabetalone has increased tremendously since 2013 and there have been no setbacks.
With independent academics now doing their own research on apabetalone and generating positive results on other indications the knowledge flow will to increase and this is filling the the gap until BoM is complete.
It was unfortunate that the ASSURE trial was statistically underpowered and that the primary endpoint was PAV regression because some of the secondary endpoints were met but the announcement made rvx-208/apabetalone look like a failure...but not to Dr Wong, Don, Eastern, NGN and Hepalink which jumped in after ASSURE.
Well, GLTA
Toinv